Your browser doesn't support javascript.
loading
Resectability and Ablatability Criteria for the Treatment of Liver Only Colorectal Metastases: Multidisciplinary Consensus Document from the COLLISION Trial Group.
Nieuwenhuizen, Sanne; Puijk, Robbert S; van den Bemd, Bente; Aldrighetti, Luca; Arntz, Mark; van den Boezem, Peter B; Bruynzeel, Anna M E; Burgmans, Mark C; de Cobelli, Francesco; Coolsen, Marielle M E; Dejong, Cornelis H C; Derks, Sarah; Diederik, Arjen; van Duijvendijk, Peter; Eker, Hasan H; Engelsman, Anton F; Erdmann, Joris I; Fütterer, Jurgen J; Geboers, Bart; Groot, Gerie; Haasbeek, Cornelis J A; Janssen, Jan-Jaap; de Jong, Koert P; Kater, G Matthijs; Kazemier, Geert; Kruimer, Johan W H; Leclercq, Wouter K G; van der Leij, Christiaan; Manusama, Eric R; Meier, Mark A J; van der Meijs, Bram B; Melenhorst, Marleen C A M; Nielsen, Karin; Nijkamp, Maarten W; Potters, Fons H; Prevoo, Warner; Rietema, Floris J; Ruarus, Alette H; Ruiter, Simeon J S; Schouten, Evelien A C; Serafino, Gian Piero; Sietses, Colin; Swijnenburg, Rutger-Jan; Timmer, Florentine E F; Versteeg, Kathelijn S; Vink, Ted; de Vries, Jan J J; de Wilt, Johannes H W; Zonderhuis, Barbara M; Scheffer, Hester J.
Afiliación
  • Nieuwenhuizen S; Department of Radiology and Nuclear Medicine, Amsterdam UMC, location VUmc, 1081 HV Amsterdam, The Netherlands.
  • Puijk RS; Department of Radiology and Nuclear Medicine, Amsterdam UMC, location VUmc, 1081 HV Amsterdam, The Netherlands.
  • van den Bemd B; Department of Radiology and Nuclear Medicine, Amsterdam UMC, location VUmc, 1081 HV Amsterdam, The Netherlands.
  • Aldrighetti L; Department of Surgical Oncology, San Raffaele Hospital, 20132 Milan, Italy.
  • Arntz M; Department of Radiology, Nuclear Medicine and Anatomy, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
  • van den Boezem PB; Department of Surgical Oncology, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
  • Bruynzeel AME; Department of Radiation Oncology, Amsterdam UMC, location VUmc, 1081 HV Amsterdam, The Netherlands.
  • Burgmans MC; Department of Radiology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
  • de Cobelli F; Department of Radiology, San Raffaele Hospital, 20132 Milan, Italy.
  • Coolsen MME; Department of Surgical Oncology, Maastricht University Medical Center, 6229 HX Maastricht, The Netherlands.
  • Dejong CHC; Department of Surgical Oncology, Maastricht University Medical Center, 6229 HX Maastricht, The Netherlands.
  • Derks S; Department of Medical Oncology, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands; Oncode Institute, 3521 AL Utrecht, The Netherlands.
  • Diederik A; Department of Radiology, Ziekenhuis Gelderse Vallei, 6716 RP Ede, The Netherlands.
  • van Duijvendijk P; Department of Surgical Oncology, Gelre Ziekenhuizen, 7334 DZ Apeldoorn, The Netherlands.
  • Eker HH; Department of Surgical Oncology, Medical Center Leeuwarden, 8934 AD Leeuwarden, The Netherlands.
  • Engelsman AF; Department of Surgical Oncology, Amsterdam UMC, location VUmc, 1081 HV Amsterdam, The Netherlands.
  • Erdmann JI; Department of Surgical Oncology, Amsterdam UMC, location VUmc, 1081 HV Amsterdam, The Netherlands.
  • Fütterer JJ; Department of Radiology, Nuclear Medicine and Anatomy, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
  • Geboers B; Department of Radiology and Nuclear Medicine, Amsterdam UMC, location VUmc, 1081 HV Amsterdam, The Netherlands.
  • Groot G; Department of Radiology, Ziekenhuis Gelderse Vallei, 6716 RP Ede, The Netherlands.
  • Haasbeek CJA; Department of Radiation Oncology, Amsterdam UMC, location VUmc, 1081 HV Amsterdam, The Netherlands.
  • Janssen JJ; Department of Radiology, Nuclear Medicine and Anatomy, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
  • de Jong KP; Department of Hepato-Pancreato-Biliary Surgery and Liver Transplantation, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.
  • Kater GM; Department of Radiology, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands.
  • Kazemier G; Department of Surgical Oncology, Amsterdam UMC, location VUmc, 1081 HV Amsterdam, The Netherlands.
  • Kruimer JWH; Department of Radiology, Maxima Medical Center, 5504 DB Veldhoven, The Netherlands.
  • Leclercq WKG; Department of Surgical Oncology, Maxima Medical Center, 5504 DB Veldhoven, The Netherlands.
  • van der Leij C; Department of Radiology, Maastricht University Medical Center, 6229 HX Maastricht, The Netherlands.
  • Manusama ER; Department of Surgical Oncology, Medical Center Leeuwarden, 8934 AD Leeuwarden, The Netherlands.
  • Meier MAJ; Department of Radiology, Isala Ziekenhuis, 8025 AB Zwolle, The Netherlands.
  • van der Meijs BB; Department of Radiology and Nuclear Medicine, Amsterdam UMC, location VUmc, 1081 HV Amsterdam, The Netherlands.
  • Melenhorst MCAM; Department of Radiology and Nuclear Medicine, Amsterdam UMC, location VUmc, 1081 HV Amsterdam, The Netherlands.
  • Nielsen K; Department of Surgical Oncology, Amsterdam UMC, location VUmc, 1081 HV Amsterdam, The Netherlands.
  • Nijkamp MW; Department of Hepato-Pancreato-Biliary Surgery and Liver Transplantation, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.
  • Potters FH; Department of Radiology, Isala Ziekenhuis, 8025 AB Zwolle, The Netherlands.
  • Prevoo W; Department of Radiology, OLVG, 1090 HM Amsterdam, The Netherlands.
  • Rietema FJ; Department of Radiology, Noordwest Ziekenhuisgroep, 1815 JD Alkmaar, The Netherlands.
  • Ruarus AH; Department of Radiology and Nuclear Medicine, Amsterdam UMC, location VUmc, 1081 HV Amsterdam, The Netherlands.
  • Ruiter SJS; Department of Hepato-Pancreato-Biliary Surgery and Liver Transplantation, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.
  • Schouten EAC; Department of Radiology and Nuclear Medicine, Amsterdam UMC, location VUmc, 1081 HV Amsterdam, The Netherlands.
  • Serafino GP; Department of Radiology, Jeroen Bosch Ziekenhuis, 5223 GZ 's-Hertogenbosch, The Netherlands.
  • Sietses C; Department of Surgical Oncology, Ziekenhuis Gelderse Vallei, 6716 RP Ede, The Netherlands.
  • Swijnenburg RJ; Department of Surgical Oncology, Amsterdam UMC, location VUmc, 1081 HV Amsterdam, The Netherlands.
  • Timmer FEF; Department of Radiology and Nuclear Medicine, Amsterdam UMC, location VUmc, 1081 HV Amsterdam, The Netherlands.
  • Versteeg KS; Department of Medical Oncology, Amsterdam UMC, location VUmc, 1081 HV Amsterdam, The Netherlands.
  • Vink T; Department of Radiology, Medical Center Leeuwarden, 8934 AD Leeuwarden, The Netherlands.
  • de Vries JJJ; Department of Radiology and Nuclear Medicine, Amsterdam UMC, location VUmc, 1081 HV Amsterdam, The Netherlands.
  • de Wilt JHW; Department of Surgical Oncology, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
  • Zonderhuis BM; Department of Surgical Oncology, Amsterdam UMC, location VUmc, 1081 HV Amsterdam, The Netherlands.
  • Scheffer HJ; Department of Radiology and Nuclear Medicine, Amsterdam UMC, location VUmc, 1081 HV Amsterdam, The Netherlands.
Cancers (Basel) ; 12(7)2020 Jul 03.
Article en En | MEDLINE | ID: mdl-32635230
ABSTRACT
The guidelines for metastatic colorectal cancer crudely state that the best local treatment should be selected from a 'toolbox' of techniques according to patient- and treatment-related factors. We created an interdisciplinary, consensus-based algorithm with specific resectability and ablatability criteria for the treatment of colorectal liver metastases (CRLM). To pursue consensus, members of the multidisciplinary COLLISION and COLDFIRE trial expert panel employed the RAND appropriateness method (RAM). Statements regarding patient, disease, tumor and treatment characteristics were categorized as appropriate, equipoise or inappropriate. Patients with ECOG≤2, ASA≤3 and Charlson comorbidity index ≤8 should be considered fit for curative-intent local therapy. When easily resectable and/or ablatable (stage IVa), (neo)adjuvant systemic therapy is not indicated. When requiring major hepatectomy (stage IVb), neo-adjuvant systemic therapy is appropriate for early metachronous disease and to reduce procedural risk. To downstage patients (stage IVc), downsizing induction systemic therapy and/or future remnant augmentation is advised. Disease can only be deemed permanently unsuitable for local therapy if downstaging failed (stage IVd). Liver resection remains the gold standard. Thermal ablation is reserved for unresectable CRLM, deep-seated resectable CRLM and can be considered when patients are in poor health. Irreversible electroporation and stereotactic body radiotherapy can be considered for unresectable perihilar and perivascular CRLM 0-5cm. This consensus document provides per-patient and per-tumor resectability and ablatability criteria for the treatment of CRLM. These criteria are intended to aid tumor board discussions, improve consistency when designing prospective trials and advance intersociety communications. Areas where consensus is lacking warrant future comparative studies.
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Guideline / Qualitative_research Idioma: En Revista: Cancers (Basel) Año: 2020 Tipo del documento: Article País de afiliación: Países Bajos

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Guideline / Qualitative_research Idioma: En Revista: Cancers (Basel) Año: 2020 Tipo del documento: Article País de afiliación: Países Bajos